The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Many studies have shown that genetic polymorphisms of the CYP2C9 gene contribute to some of the variability (around 20%) in warfarin dose requirements and therapeutic response to the drug. It is also clear that this effect must be elicited through difference...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dickinson, Gemma L, Lennard, Martin S, Tucker, Geoffrey T, Rostami-Hodjegan, Amin
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2007
Assuntos:
Pharmacokinetics & Pharmacodynamics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000610/
https://ncbi.nlm.nih.gov/pubmed/17298479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02850.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados